Myanmar: I have defeated TB and I wish the same for other patients
April 8, 2024Multi-drug resistant tuberculosis is one of the most complex types of tuberculosis you can get. As opposed to drug-sensitive, which responds well to the medication, multi-drug resistant tuberculosis, by its very name, is resistant to some of the drugs used...
Read moreMSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction
September 19, 2023Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test. This reduction is a significant step, considering the...
Read moreAhead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need
September 12, 2023TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...
Read moreMSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
July 18, 2023MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...
Read moreMSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read moreTuberculosis: Promising new tuberculosis drug pretomanid approved, but will it be affordable?
August 15, 2019GENEVA/NEW YORK – Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the approval by the US Food and Drug Administration (FDA) of a combination regimen containing a new drug, pretomanid, for the treatment of extensively drug-resistant tuberculosis (XDR-TB). As the third...
Read more